Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04203342 · ClinicalTrials.gov registry record · Phase 3
A Therapeutic Equivalence Study of Ketoconazole Cream 2%
A Phase 3 study of Tinea Pedis, sponsored by Douglas Pharmaceuticals America.
- Completed
- Registry status
- Phase 3
- Development phase
- 682
- Enrollment target
- 3
- Study locations
NCT04203342 is a Phase 3 study of Tinea Pedis that has completed, run by Douglas Pharmaceuticals America. The registered enrollment target is 682 participants, above the 251-participant average among 9 other Tinea Pedis trials with a reported enrollment target (172% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT04203342, a Phase 3 study of Tinea Pedis, has completed, sponsored by Douglas Pharmaceuticals America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 682 participants
- Enrollment target
- 3
- Study locations
Study Summary
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.
Conditions Studied
Interventions
- DRUG Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)
- DRUG Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)
- DRUG Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Study Locations (3)
Florida
- Moore Clinical Research - Brandon
- Moore Clinical Reseach - Tampa
Other
- FXM Research International - Belize City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2020-07-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04203342
The ClinicalTrials.gov registry entry for NCT04203342 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 251-participant average among 9 other Tinea Pedis trials with a reported enrollment target (172% higher). The listed sponsor is Douglas Pharmaceuticals America, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tinea Pedis appearing as the primary indexed condition, and to 3 interventions - of which Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.) is the first listed.
NCT04203342 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Other.
Frequently Asked Questions
What is clinical trial NCT04203342 about?
NCT04203342 is a clinical study titled "A Therapeutic Equivalence Study of Ketoconazole Cream 2%". Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.
What is the current status of trial NCT04203342?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2019-12-11. Estimated completion is 2020-07-13.
What conditions does trial NCT04203342 study?
This clinical trial studies the following conditions: Tinea Pedis.
What interventions are being tested in trial NCT04203342?
The interventions under investigation include: Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.) (DRUG), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA) (DRUG), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.) (DRUG).
Who is sponsoring clinical trial NCT04203342?
This trial is sponsored by Douglas Pharmaceuticals America, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04203342 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis
COMPLETED · Phase 3
-
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
COMPLETED · Phase 3
-
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
RECRUITING · Phase 2
-
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
COMPLETED · Phase 1
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.